Â Â UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C.Â 20549Â FORM 6-KÂ Report of Foreign Private IssuerPursuant to Rule 13a-16 or 15d-16ofÂ the Securities Exchange Act of 1934Â For the month of February 2025Commission File Number: 001-37643Â PURPLE BIOTECH LTD.(Translation of registrantâ€™s name into English)Â 4 Oppenheimer Street, Science Park, Rehovot7670104, Israel(Address of principal executive offices)Â Indicate by check mark whether the registrant files or will file annualreports under cover Form 20-F or Form 40-F.Â Â Form 20-F â˜’Â Â Â Form 40-F â˜Â Â Â Â Â Â On February 3, 2025,Purple Biotech Ltd. (the â€œCompanyâ€ or the â€œRegistrantâ€) issued a press release, â€œPurpleBiotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody Platformâ€,which is attached hereto as Exhibit 99.1.Â Exhibit Â Â 99.1 Â Press Release issued by Purple Biotech Ltd. on February 3, 2025 Â Incorporation by ReferenceÂ This Report on Form 6-K, including all exhibits attached hereto, ishereby incorporated by reference into each of the Registrantâ€™s Registration Statement onÂ FormS-8Â filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrantâ€™sRegistration Statement onÂ FormS-8Â filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrantâ€™sRegistration Statement onÂ FormF-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195),the Registrantâ€™s Registration Statement onÂ FormS-8Â filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrantâ€™sRegistration Statement onÂ FormF-3Â filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrantâ€™sRegistration Statement onÂ FormF-1Â filed with the Securities and Exchange Commission on December 27, 2019 (Registration file number 333-235729), the Registrantâ€™sRegistration Statement onÂ FormF-3Â filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333-238229), the Registrantâ€™sRegistration Statement onÂ FormS-8Â filed with the Securities and Exchange Commission on May 18, 2020 (Registration file number 333-238481), each of the Registrantâ€™sRegistration Statements onÂ FormF-3Â filed with the Securities and Exchange Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793),the Registrantâ€™s Registration Statement onÂ FormS-8Â filed with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107) and the Registrantâ€™sRegistration Statement onÂ FormF-3Â filed with the Securities and Exchange Commission on March 23, 2023 (Registration file number 333-270769), the Registrantâ€™sRegistration Statement onÂ FormF-3, as amended, originally filed with the Securities and Exchange Commission on December 8, 2022 (Registration file number 333-268710),the Registrantâ€™s Registration Statement onÂ FormF-1,Â as amended, originally filed with the Securities and Exchange Commission on October 30, 2023 (Registration file number333-275216) and the Registrantâ€™s Registration Statement onÂ FormF-1,Â filed with the Securities and Exchange Commission on July 22, 2024 (Registration file number 333-280947), to be apart thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filedor furnished.Â 1 Â Â SIGNATURESÂ Pursuant to the requirementsof the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereuntoduly authorized.Â February 3, 2025 PURPLE BIOTECH LTD. Â Â Â By: /s/ Gil Efron Â Â Gil Efron Â Â Chief Executive Officer Â Â 2Â Exhibit 99.1Â PurpleBiotech Announces Research Collaboration with the Icahn School of Medicine at Mount Sinai for CAPTN-3 Tri-Specific Antibody PlatformÂ â—Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing tumor-specific immunity against multiple cancer types.Â â—CAPTN-3 antibodies are designed to promote innate-like antitumor functions by NK and CD8 T cells, through conditional activation of the anti-CD3 arm at the TME, blockade of NKG2A, and targeting tumor-specific antigens, potentially leading to improved responses in resistant cancer patients and overcoming the limitations of current therapies.Â REHOVOT, Israel, Feb. 03, 2025 (GLOBENEWSWIRE) -- Purple Biotech Ltd. (â€œPurple Biotechâ€ or â€œthe Companyâ€) (NASDAQ/TASE: PPBT), a clinical-stagecompany developing first-in-class therapies that overcome tumor immune evasion and drug resistance, announced today that it hasentered into a Research Collaboration Agreement with the Icahn School of Medicine at Mount Sinai (â€œIcahn School ofMedicineâ€) in New York, NY, to explore the immunoregulation of NK and T cells within the TME by Purpleâ€™s CAPTN-3multi-specific engagers with the purpose of enhancing tumor-specific immunity against various cancer types.Â â€œPartneringon this important preclinical work with the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Instituteat the Icahn School of Medicine is expected to deepen our understanding of the mechanisms of action for our innovative tri-specific platformin preparation for human clinical studies,â€ said Gil Efron, Purple Biotech CEO. â€œWe have recently observed a growinginterest in multi-specific engagers, and we look forward to advancing CAPTN-3 development as we prepare for first-in-human clinical studies.â€Â The Principal Investigator of the study is AmirHorowitz, PhD, Associate Professor of Immunology & Immunotherapy and Oncological Sciences and a member of the Lipschultz PrecisionImmunology Institute and The Tisch Cancer Institute. Dr. Horowitz, an expert in the immunoregulation of the TME in cancer patients, hasdemonstrated a novel immunotherapeutic target axis involving the interaction between HLA-E expressing tumor cells and NKG2A-positive NKand CD8 T cells, which suppresses immune responses in treatment-resistant patients. He and others have shown the HLA-E/NKG2A axis to bea dominant inhibitory checkpoint pathway in solid tumors.Â Dr. Horowitz commented, â€œCAPTN-3â€™sdual potential mechanisms of action appear to be a promising indicator of the platformâ€™s potential safety and efficacy to treatcancer through its synergistic regulation of both T cells and NK cells at the tumor microenvironment. In this collaboration, we plan tomap how CAPTN-3 antibodies alter T and NK cell activation within the TME, specifically focusing on the modulation of HLA-E/NKG2A interactionsand enhancing features of innate immunity.â€Â â€œThe opportunity to deepen our understandingof the tumor immune evasion mechanisms that CAPTN-3 uniquely addresses is exciting, and we hope it will pave the way for effective treatmentsfor many challenging tumor indications. We are looking forward to working with Dr. Horowitz and his team at Mount Sinai to validate theunique aspects of CAPTN-3 design in a wide screen of patient-derived tumors, potentially bringing new insights for overcoming resistanceto standard frontline immunotherapies,â€ stated Purple Biotechâ€™s VP Research and Development, Dr. Hadas Reuveni.Â Â Â In the past, Dr. Horowitz had been a paid consultant for Purple Biotech.Â About Purple BiotechÂ Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stagecompany developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance. The Companyâ€™s oncology pipelineincludes CM24, NT219, and CAPTN-3. CM24 is a humanized monoclonal antibody that blocks CEACAM1, which supports tumor immune evasion andsurvival through multiple pathways. CEACAM1 on tumor cells, immune cells and neutrophils extracellular traps is a novel target for thetreatment of multiple cancer indications. As a proof of concept of these novel pathways, the Company completed a Phase 2 study for thetreatment of pancreatic ductal adenocarcinoma (PDAC) with CM24 as a combination therapy with

the anti-PD-1 checkpoint inhibitor nivolumaband chemotherapy, demonstrating clear and consistent improvement across all efficacy endpoints and the identification of two potentialserum biomarkers. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. A Phase 1 dose escalationstudy was concluded as a monotherapy and in combination with cetuximab, in which NT219 demonstrated anti-tumor activity in combinationwith cetuximab in second-line patients with recurrent and/or metastatic SCCHN (R/N SCCHN). The Company is advancing CAPTN-3, a preclinicalplatform of conditionally-activated tri-specific antibody that engages both T cells and NK cells to induce a strong, localized immuneresponse within the tumor microenvironment. The cleavable capping technology confines the compoundâ€™s therapeutic activity to the localtumor microenvironment, thereby potentially increasing the anticipated therapeutic window in patients. The third arm specifically targetsthe Tumor Associated Antigen (TAA). The technology presents a novel mechanism of action by unleashing both innate and adaptive immunesystems to mount an optimal anti-tumoral immune response. IM1240 is the first tri-specific antibody in development that targets 5T4 expressedin a variety of solid tumors and is correlated with advanced disease, increased invasiveness, and poor clinical outcomes. The Companyâ€™scorporate headquarters are located in Rehovot, Israel. For more information, please visitÂ https://purple-biotech.com/.Â Forward-Looking Statements and Safe Harbor StatementÂ Certain statements in this press release thatare forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisionsof the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements thatare not statements of historical fact, and may be identified by words such as â€œbelieveâ€, â€œexpectâ€, â€œintendâ€,â€œplanâ€, â€œmayâ€, â€œshouldâ€, â€œcouldâ€, â€œmightâ€, â€œseekâ€, â€œtargetâ€, â€œwillâ€,â€œprojectâ€, â€œforecastâ€, â€œcontinueâ€ or â€œanticipateâ€ or their negatives or variations of these wordsor other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place unduereliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our currentviews, expectations, beliefs, or intentions with respect to future events, and are subject to a number of assumptions, involve known andunknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performanceor achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-lookingstatements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans,strategies and objectives of management for future operations; product development for NT219, CM24 and IM1240; the process by which suchearly-stage therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks,particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthyand expensive process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products; theexpense, length, progress and results of any clinical trials; the impact of any changes in regulation and legislation that could affectthe pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; thedifficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products;the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surroundingthe actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competingproducts; patents obtained by competitors; dependence on the effectiveness of our patents and other protections for innovative products;our ability to obtain, maintain and defend issued patents; the commencement of any patent interference or infringement action againstour patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation,including patent litigation, and/or regulatory actions, and other factors that are discussed in our Annual Report on Form 20-F for theyear ended December 31, 2023, and in our other filings with the U.S. Securities and Exchange Commission (â€œSECâ€), including ourcautionary discussion of risks and uncertainties under â€œRisk Factorsâ€ in our Registration Statements and Annual Reports. Theseare factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those wehave listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date on which itis made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information containedherein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however,to consult any additional disclosures we make in our reports to the SEC, which are available on the SECâ€™s website, https://www.sec.gov.Â CONTACTS:Â Company Contact:IR@purple-biotech.comÂ Â Â Â Â